Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients

Apr 7, 2005Diabetes, obesity & metabolism

Sibutramine's effects on belly fat, insulin resistance, and blood pressure in obese patients with high blood pressure

AI simplified

Abstract

Sibutramine induced a 6.7% weight reduction compared to 2.5% with placebo in hypertensive obese patients.

  • Sibutramine was associated with a reduction in waist/hip ratio (WHR) from 0.97 to 0.94, while placebo showed no significant change.
  • Insulin resistance, measured by the IRIp index, decreased with sibutramine from 0.11 to 0.09, compared to no change with placebo.
  • Visceral fat (VF) levels decreased from 6.4 cm to 6.0 cm only in the sibutramine group.
  • Plasma leptin levels remained stable during sibutramine therapy, while they decreased with placebo treatment.
  • No significant changes in lipid profiles or blood pressure were observed in either group, although heart rate increased with sibutramine.

AI simplified

Full Text

Full text is available at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free